Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
J Control Release. 2024 Jun;370:479-489. doi: 10.1016/j.jconrel.2024.04.041. Epub 2024 May 8.
Scramblase Xk-related protein 8 (Xkr8) regulates the externalization of phosphatidylserine (PS) during apoptosis and holds a pivotal role in fostering tumor immunosuppression. Targeting Xkr8 in conjunction with chemotherapy demonstrated a novel avenue for amplifying antitumor immune response and overcoming chemo-immune resistance. Here we further evaluated this strategy by using a clinically relevant orthotopic model and elucidated the mechanism through in-depth single-cell RNA sequencing (scRNA-seq). We found that Xkr8 knockdown exhibited the potential to lead to immunogenic cell death (ICD) by impeding the normal clearance of apoptotic cells. Co-delivery of Xkr8 small interference RNA (siRNA) and a prodrug conjugate of 5-fluorouracil (5-Fu) and oxoplatin (FuOXP) showed remarkable therapeutic efficacy in an orthotopic pancreatic tumor model with increased infiltration of proliferative NK cells and activated macrophages in the tumor microenvironment (TME). Single-cell trajectory analysis further unveiled that tumor infiltrating CD8 T cells are differentiated favorably to cytotoxic over exhausted phenotype after combination treatment. Our study sheds new light on the impact of Xkr8 knockdown on TME and solidifies the rationale of combining Xkr8 knockdown with chemotherapy to treat various types of cancers.
Xk 相关蛋白 8(Xkr8)调节凋亡过程中磷脂酰丝氨酸(PS)的外翻,在促进肿瘤免疫抑制方面起着关键作用。联合化疗靶向 Xkr8 为增强抗肿瘤免疫反应和克服化疗免疫抵抗提供了新途径。在这里,我们通过使用临床相关的原位模型进一步评估了这一策略,并通过深入的单细胞 RNA 测序(scRNA-seq)阐明了其机制。我们发现,通过阻止凋亡细胞的正常清除,Xkr8 敲低有可能导致免疫原性细胞死亡(ICD)。Xkr8 小干扰 RNA(siRNA)和 5-氟尿嘧啶(5-Fu)和奥沙利铂(FuOXP)前药偶联物的共同递送在原位胰腺肿瘤模型中显示出显著的治疗效果,肿瘤微环境(TME)中增殖性 NK 细胞和活化的巨噬细胞浸润增加。单细胞轨迹分析进一步揭示,联合治疗后,肿瘤浸润性 CD8 T 细胞向细胞毒性表型而非耗竭表型分化有利。我们的研究揭示了 Xkr8 敲低对 TME 的影响,并证实了联合 Xkr8 敲低与化疗治疗各种类型癌症的原理。